### ü´Å Critical Care Medicine: Digital Clubbing Diagnosis

#### ‚úÖ True Statements
1. **Digital clubbing** is the most common manifestation of **hypertrophic osteoarthropathy (HOA)**.
2. **Digital clubbing** is characterized by **increased fingertip mass** and **increased nail plate curvature**.
3. **Digital clubbing** can be **acquired** or **hereditary**.
4. **Acquired bilateral digital clubbing** is often associated with **pulmonary or cardiovascular diseases**, including **lung cancer**, **chronic obstructive pulmonary disease (COPD)**, and **interstitial lung disease (ILD)**.
5. **Onycholysis** is defined as **distal separation** of the **nail plate** from the **underlying nail bed**.
6. **Onycholysis** is usually associated with **trauma**, **psoriasis**, **contact dermatitis**, and **certain medications**.
7. **Onychomycosis** is a **fungal infection** of the **nail unit**.
8. **Onychomycosis** is characterized by **nail thickening** and **nail discoloration**.

#### üè∑Ô∏è Tags
#Pulmonology #HospitalCare #DigitalClubbing #HypertrophicOsteoarthropathy #Onycholysis #Onychomycosis

#### üìö Reference
American College of Physicians. MKSAP 19 ‚Äî Critical Care Medicine: *Answer & Critique for CCVDX24008 (Digital Clubbing Diagnosis).* Updated 2025.

#### üÜî Question ID
CCVDX24008

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures
<figure>
  <img src="Diagnose digital clubbing.png" alt="Diagnose digital clubbing.png">
  <figcaption><strong>Figure: Diagnose digital clubbing</strong>.</figcaption>
</figure>

---

#### üìñ Related Text
MKSAP 19 ‚Äî Critical Care Medicine: Common ICU Conditions (Acute Respiratory Failure; Acute Inhalational Injuries; Acute Respiratory Distress Syndrome; Ventilatory and Nonventilatory Management of ARDS; Acute Heart Failure; Atelectasis; Pneumonia; Diffuse Parenchymal Lung Disease).

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Hypoxemic respiratory failure** is caused by **inadequate oxygenation of hemoglobin**.
2. **Shunt (ventilation‚Äìperfusion [V/Q] mismatch with V/Q = 0)** is the most common mechanism of **hypoxemic respiratory failure** and reflects **perfusion of nonventilated lung regions**.
3. The two main causes of **shunt** are **alveolar collapse (atelectasis)** and **alveolar filling with blood, cells, protein, or water**.
4. Less common causes of **shunt** include **fistulas** and **cardiac or pulmonary vessel malformations**.
5. A key feature of **shunt** is an **increased alveolar‚Äìarterial oxygen (A‚Äìa O‚ÇÇ) gradient** that is **not responsive to oxygen supplementation**.
6. The **alveolar gas equation** is: **Alveolar P_O‚ÇÇ = (F_IO‚ÇÇ √ó [P_atm ‚àí 47]) ‚àí (1.25 √ó P_CO‚ÇÇ)**.
7. The **calculated A‚Äìa O‚ÇÇ gradient** should be **compared with the expected gradient** based on **age** and **fraction of inspired oxygen (F_IO‚ÇÇ)**.
8. **V/Q mismatch** (other than pure shunt) can also **increase the A‚Äìa O‚ÇÇ gradient**, whereas **alveolar hypoventilation** produces **hypoxemia with a normal A‚Äìa O‚ÇÇ gradient**.
9. Clinical features of **acute hypoxemic respiratory failure** include **recent onset of increased work of breathing, tachypnea, and anxiety**.
10. **Cyanosis of the lips and fingers** indicates **severely compromised hemoglobin oxygenation** in **acute hypoxemic respiratory failure**.
11. **Crackles, wheezing, egophony, or rhonchi** on auscultation may indicate **underlying causes** of **acute hypoxemic respiratory failure**.
12. **Clubbing** suggests **chronic diseases** such as **bronchiectasis, idiopathic pulmonary fibrosis (IPF),** or **lung cancer**.
13. **Chest imaging** can help **identify the cause** of **acute respiratory failure**.
14. Treatment of **hypoxemic respiratory failure** includes **supplemental oxygen**, **mechanical ventilation with positive end-expiratory pressure (PEEP)** to **open alveoli**, and, in **severe cases**, **extracorporeal membrane oxygenation (ECMO)**.

15. After **smoke inhalation**, approximately **one third of patients** develop **airway edema** or **mucosal sloughing** caused by **epithelial necrosis**.
16. **Direct thermal injury** from **smoke inhalation** is usually **limited to the upper airways**, whereas **steam inhalation** can cause **thermal injury throughout the tracheobronchial tree**.
17. Following **smoke inhalation**, **early intubation, chest physiotherapy, and serial bronchoscopy** are frequently used to **facilitate airway clearance**.
18. **Chemical constituents of smoke** can injure the **distal airways and lung parenchyma**, causing **bronchoconstriction, pulmonary edema, V/Q mismatch, and bronchial cast formation**; **treatment is supportive**.
19. **Secondary infections** are common after **smoke inhalation**, and **pneumonia** is the **most frequent complication**, especially due to **Staphylococcus** and **Pseudomonas** species.
20. **Carbon monoxide** and **hydrogen cyanide** toxicities are **common after smoke exposure** and should be **suspected in all exposed patients**.
21. **Water‚Äësoluble chemical vapors** predominantly affect the **upper airway** with **rapid symptom onset**, while **water‚Äëinsoluble vapors** more often affect the **lung parenchyma and distal airways** with **delayed symptoms**.
22. **Inhalational injuries from chemical vapors** commonly cause **edema, bronchospasm, asphyxiation, and direct systemic toxicity**; **treatment is supportive**.
23. In **cholinesterase inhibitor (organophosphate) exposure**, **high‚Äëdose atropine** is administered **until bronchorrhea and bronchospasm are controlled**.
24. **E‚Äëcigarette‚Äì or vaping‚Äëassociated lung injury (EVALI)** is linked to **vitamin E acetate** used to **thicken illicit vaping products**.
25. Suspicion for **EVALI** should be **high** in **e‚Äëcigarette or vaping device users** with **hypoxemia**, **respiratory symptoms (cough, dyspnea)**, and **gastrointestinal symptoms (abdominal pain, vomiting, diarrhea)**, with possible **fever or chills**.
26. **Reported EVALI cases** have **declined sharply since 2019** after **public awareness increased** and **vitamin E acetate was removed** from affected products.
27. **EVALI treatment** is **supportive**; **empiric antibiotics** are often given if **infection cannot be ruled out**, and **systemic glucocorticoids** may be **useful in severe disease**.

28. **Acute respiratory distress syndrome (ARDS)** is defined by **acute hypoxemia** and **diffuse lung injury** due to an **inciting insult**, most commonly **sepsis** or **pneumonia**.
29. In **ARDS**, **surfactant disruption**, **vascular endothelial injury**, and **alveolar epithelial injury** lead to **fluid and protein extravasation**, **alveolar collapse**, **V/Q mismatch**, and **decreased lung compliance**.
30. **No specific diagnostic test** exists for **ARDS**; a **2023 global consensus definition** provides **diagnostic criteria**.
31. Patients with **ARDS** are at **high risk of mortality**, most often from **underlying disease, secondary infection, or multiorgan dysfunction** rather than **refractory hypoxemia**.

32. Most patients with **ARDS** are managed with **invasive mechanical ventilation**.
33. **Low tidal volume ventilation** and **PEEP** are **cornerstones of ARDS management** and are **associated with improved outcomes**.
34. **Heterogeneous lung involvement** in **ARDS** makes **compliant regions** susceptible to **overdistention (volutrauma)**, which is **mitigated by low tidal volumes**.
35. Guidelines recommend a **tidal volume of 4‚Äì8 mL/kg predicted body weight** and a **plateau pressure <30 cm H‚ÇÇO**, supported by evidence of an **11% absolute mortality reduction**.
36. **PEEP** prevents **atelectrauma** from **repetitive opening and closing** of distal airways and **improves V/Q matching** by **maintaining alveolar recruitment**.
37. There is **no universal optimal PEEP**; a **PEEP‚ÄìF_IO‚ÇÇ table** is used to **match PEEP to required F_IO‚ÇÇ** to maintain a **target oxygen saturation of 88%‚Äì95%**.
38. Guidelines **conditionally recommend higher PEEP** (but **not lung recruitment maneuvers**) for **moderate to severe ARDS**.
39. **Prone positioning** reduces **dependent lung compression**, improves **V/Q matching**, and **improves mortality** when used **early (within 48 hours)** with **low tidal volume ventilation** in patients with **P_aO‚ÇÇ/F_IO‚ÇÇ <150 mm Hg**.
40. **Prone positioning** for **‚â•12‚Äì16 hours/day** should be **considered** for **severe ARDS** (defined as **P_aO‚ÇÇ/F_IO‚ÇÇ <150 mm Hg** with **F_IO‚ÇÇ ‚â•0.6**).
41. **Venovenous ECMO** is an **option** for **ARDS** unresponsive to **conventional management**; **early evaluation** for **ECMO appropriateness** is **recommended** in **severe ARDS**.
42. The following ventilator strategies **have not demonstrated a mortality benefit** in **ARDS**: **inverse‚Äëratio ventilation, airway pressure release ventilation (APRV), esophageal pressure monitoring, driving pressure‚Äìguided PEEP titration,** and **high‚Äëfrequency oscillatory ventilation**.

43. **Light sedation** with **daily awakening**, **frequent reassessment**, and **minimization of mind‚Äëaltering medications** is recommended to **limit complications** of **sedative and opioid medications** in **ARDS/ICU care**.
44. **Systemic glucocorticoids** may **reduce mortality** in **moderate to severe ARDS** and are **conditionally recommended**.
45. A **conservative fluid strategy** in **ARDS** improves **oxygenation** and **reduces duration** of **mechanical ventilation** and **ICU stay** compared with a **liberal fluid strategy**.
46. In **ARDS** patients **without hypotension or organ hypoperfusion**, **protocol‚Äëdirected diuretics** and **minimal intravenous fluids** are recommended.
47. **Neuromuscular blocking agents** may **improve oxygenation** and **reduce ventilator‚Äëinduced lung injury** in **ARDS** but **should not be used routinely**.
48. Recent evidence shows **no significant 90‚Äëday mortality difference** with **cisatracurium infusion** versus **lighter sedation** in **moderate to severe ARDS**, and there is a **trend toward increased ICU‚Äëacquired weakness** with paralysis.
49. The following therapies are **not recommended** in **ARDS** due to **conflicting or limited evidence**: **nutritional modifications, vitamin C, macrolide antibiotics, inhaled nitric oxide, prostacyclin analogues, stem cells,** or **granulocyte‚Äëmacrophage colony‚Äëstimulating factor (GM‚ÄëCSF)**.

50. **Acute cardiogenic pulmonary edema** commonly presents with **hypoxemic respiratory failure**.
51. Patients with **acute respiratory failure** should be **evaluated for cardiogenic causes**, including **cardiomyopathy, mitral or aortic valve disease, myocardial ischemia,** and **arrhythmias** (particularly **atrial fibrillation with rapid ventricular rate**).
52. Evaluation of suspected **acute cardiogenic pulmonary edema** includes **assessment of volume overload** (e.g., **jugular venous distention, S3, peripheral edema**), **electrocardiogram (ECG)**, **B‚Äëtype natriuretic peptide (BNP)** measurement, **serial serum troponins**, and **echocardiography**.
53. **Acute cardiogenic pulmonary edema** typically **responds promptly** to **afterload and preload reduction** with **vasodilators or inodilators**; **diuretics** are used for **longer‚Äëterm fluid management**.
54. **Noninvasive positive‚Äëpressure ventilation (PPV)** for **cardiogenic pulmonary edema** **hastens hypoxemia resolution**, **reduces preload and afterload**, **improves symptoms**, **lowers intubation rates**, and **decreases mortality** compared with **oxygen therapy alone**.

55. **Atelectasis** is a **common postoperative complication** due to **pain or impaired respiratory mechanics** that cause **shallow breathing** and **cough suppression**.
56. **Atelectasis** may be **asymptomatic** or present with **labored breathing**, **diminished basal breath sounds**, **egophony**, **rhonchi**, and **consolidation on imaging**.
57. **Management of atelectasis** includes **pain control**, **early mobility**, and **secretion management**.
58. **Respiratory physiotherapy** (e.g., **inspiratory muscle training, deep‚Äëbreathing exercise, mobility programs, percussion and vibration therapy**) **prevents and treats atelectasis**.
59. **Routine bronchoscopy** for **airway mucus clearance** offers **no clear benefit** compared with **other chest physiotherapy methods** and should be **reserved** when **24 hours** of **respiratory physiotherapy** **fails** to improve **atelectasis**.
60. When **secretions are minimal**, **positive‚Äëpressure airway therapy** (e.g., **positive expiratory pressure devices**) may be **considered** to **recruit collapsed alveoli**.
61. There is **no evidence** supporting **mucolytics such as N‚Äëacetylcysteine** for **atelectasis treatment**.

62. **Pneumonia** is a **common cause** of **respiratory failure** in the **ICU** and is the **most common cause of ARDS** that develops **outside the hospital**.
63. In patients with **appropriate clinical history**, **chest radiography** is the **standard diagnostic test** for **pneumonia**.
64. A **negative clinical examination or chest radiograph** does **not rule out community‚Äëacquired pneumonia (CAP)** in **symptomatic patients**, especially **older adults**.
65. The **absence of typical features or focal infiltrates** on **chest radiograph** should **not delay early antibiotics** when **probability of CAP is high**.
66. Some **guidelines recommend glucocorticoids** for **severe CAP** in addition to **antimicrobial therapy**.

67. **Acute exacerbations of diffuse parenchymal lung disease (DPLD)**‚Äîparticularly **idiopathic pulmonary fibrosis (IPF)**‚Äîcan occur **after inciting events** (e.g., **infection, procedures, drug reactions**) or **without an identifiable cause**.
68. Diagnostic **criteria for acute DPLD exacerbations** include **previous or concurrent DPLD**, **acute worsening of respiratory status (<1 month)**, and **new ground‚Äëglass opacities on imaging**.
69. **Mortality** for **hypoxemic respiratory failure** due to **IPF exacerbation** **exceeds 50%**.
70. Most patients with **IPF exacerbation** are treated **empirically** with **antibiotics** and **high‚Äëdose glucocorticoids or other immunosuppressants**, but **evidence is insufficient** to define **dose, duration, or certainty of benefit**.
71. Outcomes after **intubation and mechanical ventilation** for **IPF exacerbation** are **very poor**, and **mortality can approach 100%**.
72. For **IPF exacerbation with hypoxemic respiratory failure**, clinicians should **discuss goals of care early**, **consider palliative care strategies**, and offer **ECMO only as a bridge** for **transplant‚Äëeligible patients already listed** for **lung transplantation**.

#### üí¨ Extra
- (6) **Variable definitions in the alveolar gas equation**: **F_IO‚ÇÇ** = fraction of inspired oxygen (0.21 in ambient air); **P_atm** = atmospheric pressure (‚âà760 mm Hg at sea level); **47 mm Hg** = water vapor pressure at **37 ¬∞C**; multiplier **1.25** approximates **R**‚Äëadjustment using **P_CO‚ÇÇ**.
- (37) **PEEP‚ÄìF_IO‚ÇÇ table**: pairs higher **PEEP** with higher **F_IO‚ÇÇ** to meet a target **oxygen saturation of 88%‚Äì95%** rather than a single universal PEEP.
- (39‚Äì40) **Prone positioning threshold**: benefit shown when **P_aO‚ÇÇ/F_IO‚ÇÇ <150 mm Hg** and applied **early** with **low tidal volume ventilation**; typical **duration 12‚Äì16 h/day**.
- (41) **ECMO modality**: **venovenous ECMO** supports **gas exchange** in **severe ARDS** unresponsive to conventional therapy.
- (54) **Noninvasive PPV in cardiogenic pulmonary edema**: benefits include **reduced intubation** and **lower mortality** versus **oxygen alone**.
- (59) **When to consider bronchoscopy** for **atelectasis**: after **~24 hours** of **failed respiratory physiotherapy**.

#### üè∑Ô∏è Tags
#Hypoxemia #Shunt #VQMismatch #AlveolarGasEquation #ARDS #PEEP #PronePositioning #ECMO #InhalationInjury #EVALI #CardiogenicPulmonaryEdema #PPV #Atelectasis #Pneumonia #CAP #DPLD #IPF #CriticalCare

---

### üßæ Supplemental Tables (HTML)

<!-- Table 1: Key Features of Inhaled Toxins -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%">
  <caption><strong>Key Features of Inhaled Toxins</strong></caption>
  <thead>
    <tr>
      <th>Agent</th>
      <th>Characteristics</th>
      <th>Clinical Features After Exposure</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ammonia</td>
      <td>Colorless; ammonia odor</td>
      <td>Cough, upper airway burns, pulmonary edema, asphyxiation in poorly vented areas</td>
    </tr>
    <tr>
      <td>Chlorine</td>
      <td>Yellow‚Äëgreen; chlorine odor</td>
      <td>Upper airway irritation and burns, bronchospasm, pulmonary edema</td>
    </tr>
    <tr>
      <td>Phosgene</td>
      <td>Colorless; musty odor like fresh‚Äëcut grass</td>
      <td>Systemic toxicity, including elevated methemoglobin level, cyanosis, and metabolic acidosis; pulmonary edema</td>
    </tr>
    <tr>
      <td>Mustard gas</td>
      <td>Yellow‚Äëbrown vapor; odor like garlic or onions</td>
      <td>Upper airways burns and obstruction can occur</td>
    </tr>
    <tr>
      <td>Organophosphates and other cholinesterase inhibitors</td>
      <td>Colorless; fruity odor</td>
      <td>Systemic toxicity causing acetylcholine toxicity (rhinorrhea, bronchorrhea, diarrhea, bronchospasm, bradycardia, flaccid paralysis, apnea)</td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements ‚Äî Key Features of Inhaled Toxins
1. **Ammonia inhalation** is characterized by a **colorless gas with an ammonia odor** and can cause **cough, upper airway burns, pulmonary edema, and asphyxiation** in poorly ventilated areas.
2. **Chlorine inhalation** is characterized by a **yellow-green gas with a chlorine odor** and can cause **upper airway irritation and burns, bronchospasm, and pulmonary edema**.
3. **Phosgene inhalation** is characterized by a **colorless gas with a musty odor like fresh-cut grass** and can cause **systemic toxicity including elevated methemoglobin, cyanosis, metabolic acidosis, and pulmonary edema**.
4. **Mustard gas inhalation** is characterized by a **yellow-brown vapor with a garlic or onion odor** and can cause **upper airway burns and obstruction**.
5. **Organophosphate or other cholinesterase inhibitor inhalation** is characterized by a **colorless gas with a fruity odor** and can cause **acetylcholine toxicity including rhinorrhea, bronchorrhea, diarrhea, bronchospasm, bradycardia, flaccid paralysis, and apnea**.

#### üí¨ Extra
3. **Phosgene systemic toxicity** includes both **methemoglobinemia** and **metabolic acidosis** in addition to pulmonary effects.
5. **Cholinesterase inhibitor toxicity** causes both **muscarinic (secretions, bradycardia)** and **nicotinic (paralysis)** effects.

---

<!-- Table 2: Common Causes of ARDS -->
<table role="table" aria-label="Common Causes of Acute Respiratory Distress Syndrome" style="border-collapse:collapse; width:100%;" border="1" cellpadding="8" cellspacing="0">
  <caption style="caption-side:top; text-align:left;"><strong>Common Causes of Acute Respiratory Distress Syndrome</strong></caption>
  <tbody>
    <!-- Section: Direct Pulmonary Injury -->
    <tr>
      <th scope="rowgroup" colspan="1" style="text-align:left; background:#f2f2f2;">Direct Pulmonary Injury</th>
    </tr>
    <tr><td>Aspiration of gastric contents</td></tr>
    <tr><td>Fat embolism</td></tr>
    <tr><td>Near drowning</td></tr>
    <tr><td>Pneumonia (including viral causes such as COVID‚Äë19)</td></tr>
    <tr><td>Smoke or chemical inhalation</td></tr>
    <tr><td>Thoracic trauma/thoracic contusion</td></tr>
    <!-- Section: Indirect Pulmonary Injury -->
    <tr>
      <th scope="rowgroup" colspan="1" style="text-align:left; background:#f2f2f2;">Indirect Pulmonary Injury</th>
    </tr>
    <tr><td>Disseminated intravascular coagulation</td></tr>
    <tr><td>Nonthoracic trauma</td></tr>
    <tr><td>Pancreatitis</td></tr>
    <tr><td>Pulmonary reperfusion injury (after lung transplantation)</td></tr>
    <tr><td>Sepsis/septic shock</td></tr>
    <tr><td>Transfusion of blood products</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements ‚Äî Common Causes of Acute Respiratory Distress Syndrome (ARDS)
1. **Aspiration of gastric contents** is a direct pulmonary cause of **acute respiratory distress syndrome (ARDS)**.
2. **Fat embolism** is a direct pulmonary cause of **ARDS**.
3. **Near drowning** is a direct pulmonary cause of **ARDS**.
4. **Pneumonia**, including **viral pneumonia such as COVID-19**, is a direct pulmonary cause of **ARDS**.
5. **Smoke inhalation** or **chemical inhalation** are direct pulmonary causes of **ARDS**.
6. **Thoracic trauma** or **thoracic contusion** are direct pulmonary causes of **ARDS**.
7. **Disseminated intravascular coagulation (DIC)** is an indirect pulmonary cause of **ARDS**.
8. **Nonthoracic trauma** is an indirect pulmonary cause of **ARDS**.
9. **Pancreatitis** is an indirect pulmonary cause of **ARDS**.
10. **Pulmonary reperfusion injury** after **lung transplantation** is an indirect pulmonary cause of **ARDS**.
11. **Sepsis or septic shock** are indirect pulmonary causes of **ARDS**.
12. **Transfusion of blood products** is an indirect pulmonary cause of **ARDS**.

---

<!-- Table 3: 2023 New Global Definition of ARDS -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%">
  <caption><strong>2023 New Global Definition of Acute Respiratory Distress Syndrome (ARDS)</strong></caption>
  <thead>
    <tr>
      <th>Criteria</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Acute hypoxemic respiratory failure (within 1 week)</td></tr>
    <tr><td>If not intubated, high‚Äëflow nasal oxygen ‚â•30 L/min or noninvasive ventilation/CPAP ‚â•5 cm H<sub>2</sub>O end‚Äëexpiratory pressure</td></tr>
    <tr><td>Hypoxemia: P<sub>a</sub>O<sub>2</sub>/F<sub>IO2</sub> ‚â§300 mm Hg <em>or</em> S<sub>p</sub>O<sub>2</sub>/F<sub>IO2</sub> &lt;315 mm Hg with S<sub>p</sub>O<sub>2</sub> ‚â§97%</td></tr>
    <tr><td>Bilateral lung opacities confirmed by chest radiograph, CT scan, or ultrasound with a well‚Äëtrained operator</td></tr>
    <tr><td><strong>Resource‚Äëlimited settings:</strong> S<sub>p</sub>O<sub>2</sub>/F<sub>IO2</sub> &lt;315 with S<sub>p</sub>O<sub>2</sub> ‚â§97% (minimum PEEP and oxygen flow rates not required)</td></tr>
  </tbody>
  <tfoot>
    <tr>
      <td>
        <strong>Footnotes/Abbreviations:</strong> CPAP = continuous positive airway pressure; NIV = noninvasive ventilation; PEEP = positive end‚Äëexpiratory pressure; S<sub>p</sub>O<sub>2</sub> = oxygen saturation by pulse oximetry.
        <br/>
        <strong>Reference:</strong> Matthay MA, Arabi Y, Arroliga AC, et&nbsp;al. A new global definition of acute respiratory distress syndrome. <em>Am J Respir Crit Care Med.</em> 2024;209:37‚Äë47. PMID: 37487152. doi:10.1164/rccm.202303‚Äë0558WS.
      </td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements ‚Äî 2023 New Global Definition of Acute Respiratory Distress Syndrome (ARDS)
1. The **2023 global definition of acute respiratory distress syndrome (ARDS)** requires **acute hypoxemic respiratory failure within 1 week** of an inciting event.
2. In the **2023 ARDS definition**, patients not intubated must have **high-flow nasal oxygen ‚â•30 L/min** or **noninvasive ventilation/continuous positive airway pressure (CPAP) with ‚â•5 cm H‚ÇÇO end-expiratory pressure**.
3. The **2023 ARDS definition** requires **hypoxemia with a Pao‚ÇÇ/Fio‚ÇÇ ratio ‚â§300 mm Hg** or an **Spo‚ÇÇ/Fio‚ÇÇ ratio <315 mm Hg with Spo‚ÇÇ ‚â§97%**.
4. The **2023 ARDS definition** requires **bilateral lung opacities** confirmed by **chest radiograph, CT scan, or ultrasound performed by a trained operator**.
5. In **resource-limited settings**, the **2023 ARDS definition** allows diagnosis when **Spo‚ÇÇ/Fio‚ÇÇ <315 with Spo‚ÇÇ ‚â§97%**, without requiring minimum positive end-expiratory pressure (PEEP) or oxygen flow rates.

#### üí¨ Extra
2. **High-flow nasal oxygen** must deliver at least **30 liters per minute**.
3. The **oxygenation criteria** can be based on either **arterial blood gases (Pao‚ÇÇ)** or **pulse oximetry (Spo‚ÇÇ)**.

---

<!-- Table 4: PEEP‚ÄìFIO2 Table -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%">
  <caption><strong>PEEP‚ÄìF<sub>IO2</sub> Table for Selecting PEEP for the Ventilation of Patients with ARDS</strong></caption>
  <thead>
    <tr>
      <th>F<sub>IO2</sub></th>
      <th>0.3</th>
      <th>0.4</th>
      <th>0.4</th>
      <th>0.5</th>
      <th>0.5</th>
      <th>0.6</th>
      <th>0.7</th>
      <th>0.7</th>
      <th>0.8</th>
      <th>0.9</th>
      <th>0.9</th>
      <th>0.9</th>
      <th>1.0</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>PEEP (cm H<sub>2</sub>O)</th>
      <td>5</td>
      <td>5</td>
      <td>8</td>
      <td>8</td>
      <td>10</td>
      <td>10</td>
      <td>10</td>
      <td>12</td>
      <td>14</td>
      <td>14</td>
      <td>14</td>
      <td>16</td>
      <td>18‚Äì24</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="14">
        <strong>Footnotes/Abbreviations:</strong> PEEP = positive end‚Äëexpiratory pressure.
        <br/>
        <strong>Source:</strong> NIH‚ÄìNational Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network.
      </td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements ‚Äî PEEP‚ÄìFio‚ÇÇ Table for Selecting PEEP for the Ventilation of Patients with ARDS
1. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.3**, the recommended **positive end-expiratory pressure (PEEP)** is **5 cm H‚ÇÇO**.
2. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.4**, the recommended **PEEP** is **5‚Äì8 cm H‚ÇÇO**.
3. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.5**, the recommended **PEEP** is **8‚Äì10 cm H‚ÇÇO**.
4. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.6**, the recommended **PEEP** is **10 cm H‚ÇÇO**.
5. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.7**, the recommended **PEEP** is **10‚Äì12 cm H‚ÇÇO**.
6. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.8**, the recommended **PEEP** is **14 cm H‚ÇÇO**.
7. In **ARDS ventilation management**, with an Fio‚ÇÇ of **0.9**, the recommended **PEEP** is **14‚Äì16 cm H‚ÇÇO**.
8. In **ARDS ventilation management**, with an Fio‚ÇÇ of **1.0**, the recommended **PEEP** is **18‚Äì24 cm H‚ÇÇO**.

#### üí¨ Extra
2. The **PEEP‚ÄìFio‚ÇÇ table** pairs incremental increases in **PEEP** with **Fio‚ÇÇ** to maintain adequate oxygenation (typically **Spo‚ÇÇ 88%‚Äì95%**).

---

### üñºÔ∏è Supplemental Figure (HTML)

<figure>
  <img src="Diffuse Alveolar Damage in ARDS.jpg" alt="ARDS histology showing diffuse alveolar damage" style="max-width:100%; height:auto;">
  <figcaption>
    <strong>ARDS Histology Showing Diffuse Alveolar Damage.</strong>
    <br/>
    <em>Numbered features:</em>
    1 = interstitial edema (thickened cellular space between airspace and vasculature);
    2 = hyaline membranes (proteinaceous alveolar exudates that accumulate along the alveolar surfaces and impair gas exchange);
    3 = denuded epithelium (usually numerous type 1 alveolar cells that have undergone apoptosis and been replaced by hyaline membrane or fibrosis).
  </figcaption>
</figure>

---

#### üè∑Ô∏è Tags
#ARDS #CriticalCare #InhalationInjury #InhaledToxins #PEEP #Fio2 #RespiratoryFailure #Sepsis #Trauma #COVID19 #Transfusion #Aspiration #Pancreatitis